Answers are grounded in this paper and cite their sources.
Today, antiretroviral therapies are successful in chronic HIV infection and have improved survival outcome.However antiretroviral drug resistance, coinfection, comorbidity and management of drug interactions are prominent in long-term treatments.In this study, we aimed to present the management of antiretroviral treatment in the light of high levels of darunavir resistance in a patient who is incompatible with antiretroviral therapies.HIV-1 drug resistance analysis was frequently applied because our patient was not compatible with the treatment.Minimally interacting agents with antiretroviral therapy could be selected in developing pulmonary tuberculosis.In addition, in the developing acute renal failure, genetic barrier anxiety could be left behind.Our findings suggest that HIV-1 drug resistance analysis should be an integral part of the management of antiretroviral treatment in developing co-infections and comorbidities in an incompatible patient.
No takes yet. Share an insight, caveat, or question.
Deniz et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: